GSE231728 Celastrol targets LRP1 to inhibit fibroblast-macrophage crosstalk and ameliorates psoriasis progression
Conclusion: We report that celastrol targeted low-denisity lipoprotein receptor-related protein 1 (LRP1) to inhibit fibroblast secretion of CCL2 and inhibited psoriasis progression by reducing its recruitment to macrophages. The use of celastrol maybe a noveltherapeuticoption for psoriasis. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - April 20, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research
The Immunology of Psoriasis —Current Concepts in Pathogenesis
AbstractPsoriasis is one of the most common inflammatory skin diseases with a chronic, relapsing-remitting course. The last decades of intense research uncovered a pathological network of interactions between immune cells and other types of cells in the pathogenesis of psoriasis. Emerging evidence indicates that dendritic cells, TH17 cells, and keratinocytes constitute a pathogenic triad in psoriasis. Dendritic cells produce TNF- α and IL-23 to promote T cell differentiation toward TH17 cells that produce key psoriatic cytokines IL-17, IFN- γ, and IL-22. Their activity results in skin inflammation and activation and hype...
Source: Clinical Reviews in Allergy and Immunology - April 20, 2024 Category: Allergy & Immunology Source Type: research
Real-world experience of bimekizumab for adult patients with plaque psoriasis: A 16-week multicenter retrospective study
(Source: Journal of the American Academy of Dermatology)
Source: Journal of the American Academy of Dermatology - April 20, 2024 Category: Dermatology Authors: Alexander Rimke, Siddhartha Sood, Brian D. Rankin, Abrahim Abduelmula, Jorge R. Georgakopoulos, Khalad Maliyar, Ahmed Bagit, Fernejoy Leung, Lauren A. Stark, Ronald Vender, Jensen Yeung, Vimal H. Prajapati Source Type: research
Effects of a Brief Mindfulness-based Intervention in Patients with Psoriasis: A Randomized Controlled Trial
Acta Derm Venereol. 2024 Apr 19;104:adv18277. doi: 10.2340/actadv.v104.18277.ABSTRACTMindfulness is a special type of attention, namely focusing on the current moment in a non-judgmental manner. Extensive mindfulness-based interventions have been shown to have positive effects in patients with psoriasis. However, it is unclear whether brief (2-week) interventions are also beneficial. Therefore, the aim of this study was to investigate the effects of a 2-week mindfulness-based intervention in patients with psoriasis. Patients were randomly assigned to an experimental (treatment-as-usual + mindfulness-based intervention) or ...
Source: Acta Dermato-Venereologica - April 19, 2024 Category: Dermatology Authors: Markus Eckardt Laura Stadtmueller Christoph Zick J örg Kupfer Christina Schut Source Type: research
Effects of a Brief Mindfulness-based Intervention in Patients with Psoriasis: A Randomized Controlled Trial
Acta Derm Venereol. 2024 Apr 19;104:adv18277. doi: 10.2340/actadv.v104.18277.ABSTRACTMindfulness is a special type of attention, namely focusing on the current moment in a non-judgmental manner. Extensive mindfulness-based interventions have been shown to have positive effects in patients with psoriasis. However, it is unclear whether brief (2-week) interventions are also beneficial. Therefore, the aim of this study was to investigate the effects of a 2-week mindfulness-based intervention in patients with psoriasis. Patients were randomly assigned to an experimental (treatment-as-usual + mindfulness-based intervention) or ...
Source: Acta Derm Venereol A... - April 19, 2024 Category: Dermatology Authors: Markus Eckardt Laura Stadtmueller Christoph Zick J örg Kupfer Christina Schut Source Type: research
Effects of a Brief Mindfulness-based Intervention in Patients with Psoriasis: A Randomized Controlled Trial
Acta Derm Venereol. 2024 Apr 19;104:adv18277. doi: 10.2340/actadv.v104.18277.ABSTRACTMindfulness is a special type of attention, namely focusing on the current moment in a non-judgmental manner. Extensive mindfulness-based interventions have been shown to have positive effects in patients with psoriasis. However, it is unclear whether brief (2-week) interventions are also beneficial. Therefore, the aim of this study was to investigate the effects of a 2-week mindfulness-based intervention in patients with psoriasis. Patients were randomly assigned to an experimental (treatment-as-usual + mindfulness-based intervention) or ...
Source: Acta Dermato-Venereologica - April 19, 2024 Category: Dermatology Authors: Markus Eckardt Laura Stadtmueller Christoph Zick J örg Kupfer Christina Schut Source Type: research
Effects of a Brief Mindfulness-based Intervention in Patients with Psoriasis: A Randomized Controlled Trial
Acta Derm Venereol. 2024 Apr 19;104:adv18277. doi: 10.2340/actadv.v104.18277.ABSTRACTMindfulness is a special type of attention, namely focusing on the current moment in a non-judgmental manner. Extensive mindfulness-based interventions have been shown to have positive effects in patients with psoriasis. However, it is unclear whether brief (2-week) interventions are also beneficial. Therefore, the aim of this study was to investigate the effects of a 2-week mindfulness-based intervention in patients with psoriasis. Patients were randomly assigned to an experimental (treatment-as-usual + mindfulness-based intervention) or ...
Source: Acta Derm Venereol A... - April 19, 2024 Category: Dermatology Authors: Markus Eckardt Laura Stadtmueller Christoph Zick J örg Kupfer Christina Schut Source Type: research
Psoriatic arthropathy in patients with previous neoplasia: a case series of four patients treated with secukinumab and literature review
CONCLUSIONS: In conclusion, our case series, consisting of four PsA patients with concurrent neoplasia treated with secukinumab, showed no evidence of cancer progression and represents the first case of PsA described in the literature treated during active oncological disease, lending support to the safety of secukinumab for the treatment of patients with PsA and concomitant neoplasia.PMID:38639525 | DOI:10.26355/eurrev_202404_35919 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - April 19, 2024 Category: Drugs & Pharmacology Authors: U G Massafra F Giovannangeli A Migliore Source Type: research
Psoriatic arthropathy in patients with previous neoplasia: a case series of four patients treated with secukinumab and literature review
CONCLUSIONS: In conclusion, our case series, consisting of four PsA patients with concurrent neoplasia treated with secukinumab, showed no evidence of cancer progression and represents the first case of PsA described in the literature treated during active oncological disease, lending support to the safety of secukinumab for the treatment of patients with PsA and concomitant neoplasia.PMID:38639525 | DOI:10.26355/eurrev_202404_35919 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - April 19, 2024 Category: Drugs & Pharmacology Authors: U G Massafra F Giovannangeli A Migliore Source Type: research
Real-world outcomes and drug survival of brodalumab: results from the German Psoriasis Registry PsoBest
J Dermatolog Treat. 2024 Dec;35(1):2340107. doi: 10.1080/09546634.2024.2340107. Epub 2024 Apr 18.ABSTRACTBrodalumab, a human monoclonal antibody that targets interleukin-17 receptor A (IL-17RA), is approved in the US and EU for treatment of adults with moderate-to-severe plaque psoriasis. Although brodalumab has demonstrated efficacy and safety vs placebo in clinical trials of patients with psoriasis and psoriatic arthritis (PsA), real-world evidence is needed to evaluate long-term effectiveness and safety of brodalumab in routine care. This interim analysis of the German Psoriasis Registry PsoBest examined patient profile...
Source: Journal of Dermatological Treatment - April 18, 2024 Category: Dermatology Authors: Lisa Schaeffer Nesrine Ben-Anaya Christina Sorbe Stephan Jeff Rustenbach Ulrich Mrowietz Matthias Augustin Source Type: research
Efficacy of risankizumab across subgroups in patients with active psoriatic arthritis: a post hoc integrated analysis of the phase 3 KEEPsAKE 1 and KEEPsAKE 2 randomized controlled trials
J Dermatolog Treat. 2024 Dec;35(1):2342383. doi: 10.1080/09546634.2024.2342383. Epub 2024 Apr 18.ABSTRACTIn the KEEPsAKE 1 (NCT03675308) and KEEPsAKE 2 (NCT03671148) phase 3 trials, risankizumab demonstrated greater efficacy compared with placebo in patients with active psoriatic arthritis (PsA). This post hoc integrated analysis evaluated achieving the following efficacy outcomes at weeks 24 and 52 by baseline demographics and clinical characteristics: ≥20%/50%/70% improvement in American College of Rheumatology response criteria (ACR20/50/70), ≥90% improvement in Psoriasis Area and Severity Index, minimal disease act...
Source: Journal of Dermatological Treatment - April 18, 2024 Category: Dermatology Authors: Joseph F Merola April Armstrong Saakshi Khattri So Yeon Paek Byron Padilla Cuiyong Yue Huzefa Photowala Blair Kaplan Lars Erik Kristensen Source Type: research
Trips Through the Skin: Reviewing Cutaneous Drug Reactions to Psychedelics and Hallucinogens
Dermatitis. 2024 Apr 17. doi: 10.1089/derm.2023.0292. Online ahead of print.ABSTRACT Although psychedelic and hallucinogenic substances have gained popularity for therapeutic use, their dermatologic adverse effects are poorly characterized. This review characterizes the cutaneous reactions associated with psychedelic and hallucinogenic drugs. A review of PubMed and Scopus was conducted from the inception of databases to August 31, 2023. Search terms included drug names and classes (cannabis, MDMA, ecstasy, 3,4-methylenedioxymethamphetamine, psychedelics, hallucinogens, peyote, marijuana, lysergic acid diethylamide, LSD, ke...
Source: Dermatitis - April 18, 2024 Category: Dermatology Authors: Syed Minhaj Rahman Yousef Salem Aamir Hussain Source Type: research
Insulin Resistance Impairs Biological Agents Response in Moderate-to-Severe Plaque Psoriasis: Insights from a Prospective Cohort Study in China
CONCLUSION: IR is associated with lower effectiveness of biologics in patients with psoriasis.CLINICAL TRIAL REGISTRATION: [www.chictr.org.cn], identifier [ChiCTR2000036186].PMID:38634691 | DOI:10.1093/bjd/ljae147 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - April 18, 2024 Category: Dermatology Authors: Dawei Huang Xiaoyuan Zhong Yuxiong Jiang Luyang Kong Rui Ma Jiajing Lu Ying Li Yuling Shi Source Type: research
Filling the Prescription Gap: The Value of Community Support in Psoriasis Management
Br J Dermatol. 2024 Apr 18:ljae168. doi: 10.1093/bjd/ljae168. Online ahead of print.NO ABSTRACTPMID:38635917 | DOI:10.1093/bjd/ljae168 (Source: The British Journal of Dermatology)
Source: The British Journal of Dermatology - April 18, 2024 Category: Dermatology Authors: Melissa C Leeolou Kavita Y Sarin David F Fiorentino Source Type: research
Trips Through the Skin: Reviewing Cutaneous Drug Reactions to Psychedelics and Hallucinogens
Dermatitis. 2024 Apr 17. doi: 10.1089/derm.2023.0292. Online ahead of print.ABSTRACT Although psychedelic and hallucinogenic substances have gained popularity for therapeutic use, their dermatologic adverse effects are poorly characterized. This review characterizes the cutaneous reactions associated with psychedelic and hallucinogenic drugs. A review of PubMed and Scopus was conducted from the inception of databases to August 31, 2023. Search terms included drug names and classes (cannabis, MDMA, ecstasy, 3,4-methylenedioxymethamphetamine, psychedelics, hallucinogens, peyote, marijuana, lysergic acid diethylamide, LSD, ke...
Source: Dermatitis - April 18, 2024 Category: Dermatology Authors: Syed Minhaj Rahman Yousef Salem Aamir Hussain Source Type: research
